Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients, who have undergone hysterectomy for curative intent, with histologically confirmed endometrioid adenocarcinoma, serous or clear cell carcinoma, or carcinosarcoma or dedifferentiated carcinoma
Patient is a candidate for adjuvant pelvic radiation (+/- vault brachytherapy), meeting one of the following conditions:
* High grade histology OR
* Outer-half myometrial invasion and FIGO grade 1-2 OR
* FIGO stage II - IIIC1 (all gross nodal disease must be resected)
Patient is willing and able to give informed consent to participate in this clinical trial.
Age ≥18 years.
Patients who are to receive adjuvant systemic therapy in addition to pelvic radiotherapy will be eligible provided that there is at minimum a 3-week interval between any radiation treatment and chemotherapy treatments. Adjuvant systemic therapy may be given before or after radiation treatment.
Patient must be willing and able to complete the QLQ-C30 questionnaire with EN-24 companion as described in the study protocol.
Primary language of the patient must be English or, if a patient's primary language is not English, they are still able to participate provided the QLQ-C30 and EN-24 is available in their primary language.
You may not be if
Patient has had prior pelvic radiotherapy.
Patient has received neo-adjuvant systemic therapy
Patient has a contraindication to pelvic radiotherapy, such as but not limited to a connective tissue disease or inflammatory bowel disease.
Patient has a contraindication to iodinated CT contrast.
Patient has a hip prosthesis.
Clareo Health | Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
